SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX : revenue, balance sheet and financial ratios

SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX is a French company founded 64 years ago, specialized in the sector Fabrication de produits pharmaceutiques de base. Based in LEVALLOIS-PERRET (92300), this company of category ETI shows in 2023 a revenue of 16.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX (SIREN 622024180)
Indicator 2023 2021 2019 2018 2017 2016 2015
Revenue 16 307 216 € 11 620 144 € 7 995 623 € 6 835 779 € 7 952 032 € 6 731 899 € 7 626 389 €
Net income 990 817 € 727 870 € -172 681 € -355 005 € 711 296 € 621 881 € 233 388 €
EBITDA 3 089 905 € 2 265 466 € 1 440 330 € 935 050 € 2 058 293 € 1 633 142 € 864 442 €
Net margin 6.1% 6.3% -2.2% -5.2% 8.9% 9.2% 3.1%

Revenue and income statement

In 2023, SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX achieves revenue of 16.3 M€. Over the period 2015-2023, the company shows strong growth with a CAGR (compound annual growth rate) of +10.0%. Vs 2021, growth of +40% (11.6 M€ -> 16.3 M€). After deducting consumption (2.3 M€), gross margin stands at 14.0 M€, i.e. a rate of 86%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 3.1 M€, representing 18.9% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 991 k€, i.e. 6.1% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2023) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

16 307 216 €

Gross margin (2023) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

14 020 865 €

EBITDA (2023) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

3 089 905 €

EBIT (2023) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

1 279 243 €

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

990 817 €

EBITDA margin (2023) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

18.8%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 37%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 18.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.525%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

36.813%

Cash flow / Revenue (2023) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

18.454%

Repayment capacity (2023) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.023

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

50.8%

Solvency indicators evolution
SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX

Sector positioning

Debt ratio
0.53 2023
2019
2021
2023
Q1: 0.0
Med: 2.37
Q3: 50.5
Good +6 pts over 3 years

In 2023, the debt ratio of SOC ANGEVINE DE BIOTECHNO... (0.53) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
36.81% 2023
2019
2021
2023
Q1: 16.79%
Med: 41.7%
Q3: 73.64%
Average

In 2023, the financial autonomy of SOC ANGEVINE DE BIOTECHNO... (36.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.02 years 2023
2019
2021
2023
Q1: -1.58 years
Med: 0.0 years
Q3: 0.33 years
Average

In 2023, the repayment capacity of SOC ANGEVINE DE BIOTECHNO... (0.02) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 63.89. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 13.4x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

63.889

Interest coverage (2023) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

13.362

Liquidity indicators evolution
SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX

Sector positioning

Liquidity ratio
63.89 2023
2019
2021
2023
Q1: 89.3
Med: 247.01
Q3: 356.53
Watch -9 pts over 3 years

In 2023, the liquidity ratio of SOC ANGEVINE DE BIOTECHNO... (63.89) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
13.36x 2023
2019
2021
2023
Q1: 0.0x
Med: 0.36x
Q3: 7.36x
Excellent

In 2023, the interest coverage of SOC ANGEVINE DE BIOTECHNO... (13.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 51 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 117 days. Excellent situation: suppliers finance 66 days of the operating cycle (retail model). Inventory turnover is 115 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. WCR is negative (-156 days): operations structurally generate cash. Notable WCR improvement over the period (-745%), freeing up cash.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

-7 071 298 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

51 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

117 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

115 j

WCR in days of revenue (2023) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

-156 j

WCR and payment terms evolution
SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX

Positioning of SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX in its sector

Comparison with sector Fabrication de produits pharmaceutiques de base

Similar companies (Fabrication de produits pharmaceutiques de base)

Compare SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de produits pharmaceutiques de base

Frequently asked questions about SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX

What is the revenue of SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX ?

The revenue of SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX in 2023 is 16.3 M€.

Is SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX profitable?

Yes, SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX generated a net profit of 991 k€ in 2023.

Where is the headquarters of SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX ?

The headquarters of SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX is located in LEVALLOIS-PERRET (92300), in the department Hauts-de-Seine.

Where to find the tax return of SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX ?

The tax return of SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX operate?

SOC ANGEVINE DE BIOTECHNOLOGIE BIOPROX operates in the sector Fabrication de produits pharmaceutiques de base (NAF code 21.10Z). See the 'Sector positioning' section above to compare the company with its competitors.